Fortress Biotech FBIO 深 沪
已收盘 08-21 16:00:00 美东时间
2.87
+0.100
+3.61%
华盛通- 最 高2.875
- 今 开2.80
- 成交量 20.27万股
- 最 低 2.7937
- 昨 收 2.77
- 总市值 9571.73万
- 52周最高 4.53
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.18
- 委 比 -88.74%
- 总股本 3335.10万
- 历史最高 190.50
- 量 比 0.30
- 振 幅 2.94%
- 历史最低 1.325
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...
08-19 20:05
Fortress Biotech Q2 Earnings Preview
Fortress Biotech (FBIO) is scheduled to announce Q2 earnings results on Wednesday, August 12th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $18.3M (+...
08-12 05:35
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the l...
07-27 20:03
美股夜盘 | Namib Minerals涨69.74%，Replimune涨22.90%
Oculis Holding AG涨-33.98%；Fortress Biotech, Inc.涨-10.36%；Iris Acquisition Corp. II Class A涨-9.77%
06-01 08:05
Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst consensus estimate of $(0.22) by 1381.82 percent. This is a 687.5 percent increase over losses of $(0.48) per share
05-15 05:29
Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.57 percent. This is a 15.38 percent decrease over losses of $(0.26) per share from
04-01 05:19
Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M
Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review
03-31 04:17
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech and its subsidiary Cyprium Therapeutics announce the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress, as the majority shareholder, expects to receive over $100 million, enhancing its financial flexibility. The transaction follows three FDA approvals in the past 15 months and the sale of Checkpoint Therapeutics. Cyprium will continue to earn royalties and milestones from ZYCUBO sales and...
03-30 20:05
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Journey Medical Corporation (Nasdaq: DERM), a pharmaceutical company focused on dermatological treatments, announced on March 18, 2026, that it will release its year-end 2025 financial results after U.S. markets close on March 25, 2026. A conference call and audio webcast will be held on March 25 at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join by dialing 1-866-777-2509 (U.S.) or 1-412-317-5413 (interna...
03-18 12:30
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
